| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/22/2013 | CA2416307C Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
| 01/22/2013 | CA2402402C Use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treating adverse effects of anti-parkinsonian drugs |
| 01/22/2013 | CA2329267C A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upflp, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 01/22/2013 | CA2325629C Crystalline forms of 1s-[1alpha (2s*,3r*), 9alpha]-6, 10-dioxo-n- (2-ethoxy-5 -oxo-tetrahydro-3 -furanyl) -9-[[(1-isoquinolyl) carbonyl]-amino] octahydro-6h -piridazino[1, 2-a][1,2] diazepin- 1-carboxamide |
| 01/21/2013 | DE202012000910U1 Systemische Darreichungsformen mit kontrollierter Freisetzung und verbesserter Stabilität Systemic dosage forms with controlled release and improved stability |
| 01/19/2013 | WO2013012430A1 Dhea bioadhesive controlled release gel |
| 01/19/2013 | CA2795991A1 Dhea bioadhesive controlled release gel |
| 01/18/2013 | DE202008018336U1 Arzneimittel-freisetzende Beschichtungen für medizinische Vorrichtungen Drug-eluting coatings for medical devices |
| 01/18/2013 | CA2746717A1 Anti-fungal diaper rash creme |
| 01/17/2013 | WO2013010140A2 Methods of diagnosing cancer |
| 01/17/2013 | WO2013010136A2 Inhibitors of bruton's tyrosine kinase |
| 01/17/2013 | WO2013010135A1 Sumoylation of serca2a and cardiovascular disease |
| 01/17/2013 | WO2013010112A1 Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses |
| 01/17/2013 | WO2013010102A2 Halogenated phenols for diagnostics, antioxidant protection and drug delivery |
| 01/17/2013 | WO2013010092A1 4-oxo-3,5,7,8-tetrahydro-4h-pyrano {4,3-d} pyrminidinyl compounds for use as tankyrase inhibitors |
| 01/17/2013 | WO2013010089A2 Inhibitors of bacterial type iii secretion system |
| 01/17/2013 | WO2013010082A2 Inhibitors of bacterial type iii secretion system |
| 01/17/2013 | WO2013010041A1 Formulations of amikacin and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis |
| 01/17/2013 | WO2013010034A2 Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers |
| 01/17/2013 | WO2013010032A1 Gel compositions of oxymetazoline and methods of use |
| 01/17/2013 | WO2013010018A2 Compositions and methods for inhibiting proteases |
| 01/17/2013 | WO2013010015A2 Combination als therapy |
| 01/17/2013 | WO2013009997A1 Composition, and method of using the composition, effective for minimizing the harmful effects associated with individuals suffering from alcohol intoxication |
| 01/17/2013 | WO2013009995A1 Stable dispersion of sterols in aqueous solutions comprising an oil for the preparation of frozen beverages |
| 01/17/2013 | WO2013009945A1 Lipid-containing psa compositions, methods of isolation and methods of use thereof |
| 01/17/2013 | WO2013009929A2 Lotions derived from renewable resources and absorbent articles comprising same |
| 01/17/2013 | WO2013009928A1 Cannabinoid formulations |
| 01/17/2013 | WO2013009910A2 Eosinophil peroxidase compositions and methods of their use |
| 01/17/2013 | WO2013009844A2 C-3 substituted bicyclooctane based hiv protease inhibitors |
| 01/17/2013 | WO2013009826A1 Conjugating amines |
| 01/17/2013 | WO2013009800A2 Compositions of alkylating agents and methods of treating skin disorders therewith |
| 01/17/2013 | WO2013009799A1 Vitamin d receptor agonists and uses thereof |
| 01/17/2013 | WO2013009737A1 5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases |
| 01/17/2013 | WO2013009735A1 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| 01/17/2013 | WO2013009678A2 Compositions and methods for the treatment of norovirus infection |
| 01/17/2013 | WO2013009586A1 Topical minocycline ointment for suppression of allergic skin responses |
| 01/17/2013 | WO2013009582A1 TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| 01/17/2013 | WO2013009543A1 Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators |
| 01/17/2013 | WO2013009527A2 Factor ixa inhibitors |
| 01/17/2013 | WO2013009519A2 Materials for treating and preventing mucosa related disease |
| 01/17/2013 | WO2013009517A1 (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS |
| 01/17/2013 | WO2013009378A1 Use of xanthophyll carotenoids to improve visual performance and neural efficiency |
| 01/17/2013 | WO2013009271A1 New improved dry powder formulation |
| 01/17/2013 | WO2013009259A1 Novel compounds and their use in therapy |
| 01/17/2013 | WO2013009186A1 Nicotinamide compositions and the therapeutic use thereof |
| 01/17/2013 | WO2013009142A2 Sustained/release pharmaceutical composition comripising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same |
| 01/17/2013 | WO2013009102A2 Cartilage cell treating agent comprising collagen, hyaluronic acid derivative, and stem cell derived from mammal umbilical cord |
| 01/17/2013 | WO2013008981A1 Spherical particles of clopidogrel bisulfate, pharmaceutical composition including same, and method for manufacturing same |
| 01/17/2013 | WO2013008928A1 Macrolide derivative |
| 01/17/2013 | WO2013008909A1 Loxoprofen sodium-containing adhesive patch for external applications |
| 01/17/2013 | WO2013008872A1 Novel compound having parp inhibitory activity |
| 01/17/2013 | WO2013008240A2 Liposomes co-encapsulating a bisphosphonate and an amphipathic agent |
| 01/17/2013 | WO2013008218A1 Stable dosage forms of arterolane and piperaquine |
| 01/17/2013 | WO2013008217A1 4 - piperidinyl compounds for use as tankyrase inhibitors |
| 01/17/2013 | WO2013008202A1 Treatment of excessive menstrual bleeding associated with uterine fibroids |
| 01/17/2013 | WO2013008182A1 Prodrugs of gaba analogs |
| 01/17/2013 | WO2013008175A1 Method for producing trans-resveratrol and the analogs thereof |
| 01/17/2013 | WO2013008164A2 Method of treating atherosclerosis in high triglyceride subjects |
| 01/17/2013 | WO2013008162A1 Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| 01/17/2013 | WO2013008095A1 Novel pyrrolo pyrimidine derivatives |
| 01/17/2013 | WO2013008093A1 Terpene analogues and uses thereof for treating neurological conditions |
| 01/17/2013 | WO2013008076A1 New crystalline form |
| 01/17/2013 | WO2013008044A1 Synthesis of (+) and (-) 1 -(5,5-diphenyltetrahydrofuran-3- yl)-n,n-dimethylmethanamine, (+) and (-) 1-(2,2-diphenyltetrahydrofuran-3-yl)-n,n- dimethylmethanamine and (+) and (-) 1-(2,2- dffhenyltetrahydrofuran-3-yl)-n-metihylmethanamine |
| 01/17/2013 | WO2013008002A1 N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator |
| 01/17/2013 | WO2013007992A1 Condensed pyrimidine nucleoside analogs as anti -viral agents |
| 01/17/2013 | WO2013007986A1 Orvinol and thevinol derivatives useful in the treatment of drug and alcohol abuse |
| 01/17/2013 | WO2013007961A1 Cosmetic and/or dermatological use of oligosaccharide compounds for preventing and treating stretch marks |
| 01/17/2013 | WO2013007960A1 Use of oligosaccharide compounds for the prevention and treatment of pathological scars |
| 01/17/2013 | WO2013007792A1 Novel th2 polarizing compounds |
| 01/17/2013 | WO2013007771A1 Method for the prevention and treatment of sepsis |
| 01/17/2013 | WO2013007768A1 Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| 01/17/2013 | WO2013007766A1 Means and methods for the treatment of pathological angiogenesis |
| 01/17/2013 | WO2013007765A1 Fused tricyclic compounds for use as inhibitors of janus kinases |
| 01/17/2013 | WO2013007763A1 MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE |
| 01/17/2013 | WO2013007762A1 Combination of an anticoagulant and avidin useful in surgical intervention and clinical procedure |
| 01/17/2013 | WO2013007742A1 Probiotic for administration to healthy young mammals during the weaning period for improving tolerance to newly introduced food stuffs |
| 01/17/2013 | WO2013007725A2 Aliskiren hemifumarate, crystal form and amorphous solid |
| 01/17/2013 | WO2013007708A1 Medicament for treatment of liver cancer |
| 01/17/2013 | WO2013007703A1 CLASS A CpG OLIGONUCLEOTIDES FOR PREVENTION OF VIRAL INFECTION IN CATS |
| 01/17/2013 | WO2013007700A1 Pharmaceutical composition comprising oleic acid, palmitic acid, linoleic acid and linolenic acid |
| 01/17/2013 | WO2013007698A1 Pharmaceutical composition for neurological disorders |
| 01/17/2013 | WO2013007676A1 Aminomethyl quinolone compounds |
| 01/17/2013 | WO2013007663A1 2-benzylsulfanyl[1,3,4]-oxadiazole derivatives, and medical use thereof |
| 01/17/2013 | WO2013007660A1 Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors |
| 01/17/2013 | WO2013007621A1 Positive allosteric modulators of nicotinic acetylcholine receptor |
| 01/17/2013 | WO2013007557A1 Pharmaceutical composition, methods for treating and uses thereof |
| 01/17/2013 | WO2013007519A1 Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
| 01/17/2013 | WO2013007518A1 Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
| 01/17/2013 | WO2013007447A2 Edible composition |
| 01/17/2013 | WO2013007387A1 Novel fxr (nr1h4) binding and activity modulating compounds |
| 01/17/2013 | WO2013007384A1 Use of lipoteichoic acid in the treatment of non-encapsulated cancer cells |
| 01/17/2013 | WO2013007383A1 Use of lipoteichoic acid in the treatment of cancer in an inflammatory state |
| 01/17/2013 | WO2013007381A1 A new therapeutical composition containing apomorphine as active ingredient |
| 01/17/2013 | WO2013007361A1 Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
| 01/17/2013 | WO2013007360A1 Controlled release pharmaceutical composition of non-ergoline dopamine agonist |
| 01/17/2013 | WO2013007184A1 Antineoplastic drug tetrahydronaphthalene amide-group compound and pharmaceutically acceptable salt, preparation method and use thereof |
| 01/17/2013 | WO2013007172A1 Platinum compounds for treating cell proliferative disease, preparation methods and uses thereof |
| 01/17/2013 | WO2013007167A1 Crystal form i of salt of dipeptidyl peptidase-iv inhibitor and preparation method and use thereof |
| 01/17/2013 | WO2013007106A1 Spiro compounds as hepatitis c virus inhibitors |
| 01/17/2013 | WO2013007003A1 Novel use of acetylacetic acid for regulating proliferation of skeletal-muscle cells |